Cargando…
γ-H2AX Kinetics as a Novel Approach to High Content Screening for Small Molecule Radiosensitizers
BACKGROUND: Persistence of γ-H2AX after ionizing radiation (IR) or drug therapy is a robust reporter of unrepaired DNA double strand breaks in treated cells. METHODS: DU-145 prostate cancer cells were treated with a chemical library ±IR and assayed for persistence of γ-H2AX using an automated 96-wel...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387170/ https://www.ncbi.nlm.nih.gov/pubmed/22768044 http://dx.doi.org/10.1371/journal.pone.0038465 |
_version_ | 1782237066411638784 |
---|---|
author | Fu, Shibo Yang, Ying Tirtha, Das Yen, Yun Zhou, Bing-sen Zhou, Ming-Ming Ohlmeyer, Michael Ko, Eric C. Cagan, Ross Rosenstein, Barry S. Chen, Shu-hsia Kao, Johnny |
author_facet | Fu, Shibo Yang, Ying Tirtha, Das Yen, Yun Zhou, Bing-sen Zhou, Ming-Ming Ohlmeyer, Michael Ko, Eric C. Cagan, Ross Rosenstein, Barry S. Chen, Shu-hsia Kao, Johnny |
author_sort | Fu, Shibo |
collection | PubMed |
description | BACKGROUND: Persistence of γ-H2AX after ionizing radiation (IR) or drug therapy is a robust reporter of unrepaired DNA double strand breaks in treated cells. METHODS: DU-145 prostate cancer cells were treated with a chemical library ±IR and assayed for persistence of γ-H2AX using an automated 96-well immunocytochemistry assay at 4 hours after treatment. Hits that resulted in persistence of γ-H2AX foci were tested for effects on cell survival. The molecular targets of hits were validated by molecular, genetic and biochemical assays and in vivo activity was tested in a validated Drosophila cancer model. RESULTS: We identified 2 compounds, MS0019266 and MS0017509, which markedly increased persistence of γ-H2AX, apoptosis and radiosensitization in DU-145 cells. Chemical evaluation demonstrated that both compounds exhibited structurally similar and biochemical assays confirmed that these compounds inhibit ribonucleotide reductase. DNA microarray analysis and immunoblotting demonstrates that MS0019266 significantly decreased polo-like kinase 1 gene and protein expression. MS0019266 demonstrated in vivo antitumor activity without significant whole organism toxicity. CONCLUSIONS: MS0019266 and MS0017509 are promising compounds that may be candidates for further development as radiosensitizing compounds as inhibitors of ribonucleotide reductase. |
format | Online Article Text |
id | pubmed-3387170 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-33871702012-07-05 γ-H2AX Kinetics as a Novel Approach to High Content Screening for Small Molecule Radiosensitizers Fu, Shibo Yang, Ying Tirtha, Das Yen, Yun Zhou, Bing-sen Zhou, Ming-Ming Ohlmeyer, Michael Ko, Eric C. Cagan, Ross Rosenstein, Barry S. Chen, Shu-hsia Kao, Johnny PLoS One Research Article BACKGROUND: Persistence of γ-H2AX after ionizing radiation (IR) or drug therapy is a robust reporter of unrepaired DNA double strand breaks in treated cells. METHODS: DU-145 prostate cancer cells were treated with a chemical library ±IR and assayed for persistence of γ-H2AX using an automated 96-well immunocytochemistry assay at 4 hours after treatment. Hits that resulted in persistence of γ-H2AX foci were tested for effects on cell survival. The molecular targets of hits were validated by molecular, genetic and biochemical assays and in vivo activity was tested in a validated Drosophila cancer model. RESULTS: We identified 2 compounds, MS0019266 and MS0017509, which markedly increased persistence of γ-H2AX, apoptosis and radiosensitization in DU-145 cells. Chemical evaluation demonstrated that both compounds exhibited structurally similar and biochemical assays confirmed that these compounds inhibit ribonucleotide reductase. DNA microarray analysis and immunoblotting demonstrates that MS0019266 significantly decreased polo-like kinase 1 gene and protein expression. MS0019266 demonstrated in vivo antitumor activity without significant whole organism toxicity. CONCLUSIONS: MS0019266 and MS0017509 are promising compounds that may be candidates for further development as radiosensitizing compounds as inhibitors of ribonucleotide reductase. Public Library of Science 2012-06-29 /pmc/articles/PMC3387170/ /pubmed/22768044 http://dx.doi.org/10.1371/journal.pone.0038465 Text en Fu et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Fu, Shibo Yang, Ying Tirtha, Das Yen, Yun Zhou, Bing-sen Zhou, Ming-Ming Ohlmeyer, Michael Ko, Eric C. Cagan, Ross Rosenstein, Barry S. Chen, Shu-hsia Kao, Johnny γ-H2AX Kinetics as a Novel Approach to High Content Screening for Small Molecule Radiosensitizers |
title | γ-H2AX Kinetics as a Novel Approach to High Content Screening for Small Molecule Radiosensitizers |
title_full | γ-H2AX Kinetics as a Novel Approach to High Content Screening for Small Molecule Radiosensitizers |
title_fullStr | γ-H2AX Kinetics as a Novel Approach to High Content Screening for Small Molecule Radiosensitizers |
title_full_unstemmed | γ-H2AX Kinetics as a Novel Approach to High Content Screening for Small Molecule Radiosensitizers |
title_short | γ-H2AX Kinetics as a Novel Approach to High Content Screening for Small Molecule Radiosensitizers |
title_sort | γ-h2ax kinetics as a novel approach to high content screening for small molecule radiosensitizers |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387170/ https://www.ncbi.nlm.nih.gov/pubmed/22768044 http://dx.doi.org/10.1371/journal.pone.0038465 |
work_keys_str_mv | AT fushibo gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers AT yangying gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers AT tirthadas gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers AT yenyun gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers AT zhoubingsen gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers AT zhoumingming gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers AT ohlmeyermichael gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers AT koericc gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers AT caganross gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers AT rosensteinbarrys gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers AT chenshuhsia gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers AT kaojohnny gh2axkineticsasanovelapproachtohighcontentscreeningforsmallmoleculeradiosensitizers |